Fig. 1From: IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutationOverall trial design. As the translational research, liquid biopsies for the IMAGENE trial will be performed at baseline, cycle 2, and after discontinuation of protocol treatment. C2; Cycle 2, mEC; metastatic esophageal cancer, mGC; metastatic gastric cancer, mHNC; metastatic head and neck cancer, mMC; metastatic melanoma, mRCC; metastatic renal cell carcinoma, mUC; metastatic urothelial carcinoma, PD-1; programmed cell death-1, PD-L1; programmed cell death ligand-1, TCR; T cell receptorBack to article page